NNE Pharmaplan

Article

NNE Pharmaplan is the world?s leading engineering and consulting company in the complex field of pharma and biotech. We cover all segments from biopharmaceuticals and vaccines to medical devices and help our customers develop, establish and improve their product manufacturing.

NNE Pharmaplan is the world’s leading engineering and consulting company in the complex field of pharma and biotech. We cover all segments from biopharmaceuticals and vaccines to medical devices and help our customers develop, establish and improve their product manufacturing.

Our customers work with us because we are born out of their industry. For more than 80 years, we have matched technical knowledge with industry experience and worked out simple or complex solutions according to our customers’ needs.

Our reason for being is “Engineering for a healthier world”. We cannot claim to save lives or cure diseases. We do not produce any medicine, but we put all our engineering and consulting capabilities behind the companies that do – our customers. When we deliver consultancy or projects, we help bringing products faster to market, decreasing the overall cost of production and ensuring patient safety.

NNE Pharmaplan employs 1,700 people at more than 30 locations around the world – spanning Europe, Asia and the Americas.

Contact information

NNE Pharmaplan
Corporate head office
Nybrovej 80
2820 Gentofte
Denmark
Email: contact@nnepharmaplan
Web: ref="http://www.nnepharmaplan.com" target="_blank">www.nnepharmaplan.com
Phone: +45 4444 7777

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Related Content